Novo’s R&D chief on layoffs: A transformation rather than a cutback
Danish drug group Novo Nordisk terminates 400 employees, mainly in Denmark. But according to CSO Mads Krogsgaard Thomsen, the firings do not equal cost cuts but rather a switch-over to a digital era.
This week, Novo Nordisk initiated a comprehensive reorganization of the company, which leaves 400 staff members of the Danish and Chinese R&D departments unemployed.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
